The Food and Drug Administration (FDA) has expanded the approval of Bimzelx (bimekizumab-bkzx) to include 3 new indications.
UCB (OTCPK:UCBJY) (OTCPK:UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic ...
Less than a year after snagging its first FDA approval in psoriasis, UCB’s blockbuster hopeful Bimzelx has picked up three ...
UCB, a global biopharmaceutical company, today announced the presentation of new four-year data in patients with moderate-to-severe plaque psoriasis treated with BIMZELX® (bimekizumab-bkzx), an ...
GlobalData on MSN1d
FDA approves UCB’s BIMZELX for multiple inflammatory conditionsBiopharmaceutical company UCB has received US Food and Drug Administration (FDA) approval for BIMZELX (bimekizumab-bkzx) to ...
Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and ...
The US Food and Drug Administration has approved bimekizumab -bkzx (Bimzelx; UCB) for adult patients with active psoriatic ...
Experts at the Skin of Color Update today in New York City highlighted recent FDA-approved dermatological treatments and ...
Oruka Therapeutics (ORKA) has received a new Buy rating, initiated by TD Cowen analyst, Tyler Van Buren. Tyler Van Buren’s rating is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback